Here is another bill that will appear on the Nov. 3rd ballot asking the voters to approve a tax payer sex changes for minors (sterilization of children) and adults.
I do not support AB 2218 and would not allow such a bill like to be consider on the Assembly floor for a vote. The dangers to our children is evident enough. Below is the article and more information I thought we as voters should know. I also link the article and what drugs are used on our children.
SACRAMENTO – Without hesitation or debate, the California Assembly voted overwhelmingly today to set up a fund using tax-payer dollars to give minors and adults cross-sex hormones and surgeries that will permanently destroy their reproductive systems.
According to author Assemblyman Miguel Santiago (D) Los Angeles, AB 2218 establishes an “LGBT Transgender Wellness Fund,” to provide grants to nonprofits, hospitals, health care clinics (like Planned Parenthood), and other medical providers that supply puberty blockers and cross-sex hormones for minors, as well as cross-sex hormones and “sex-change” operations for adults. Originally the bill asked for $15 million to start the fund, but that amount was recently removed from the bill text. Now the exact amount added to the fund will be decided by the legislature at a later date.
According to Dr. Quentin Van Meter, a board-certified pediatric endocrinologist who testified against AB 2218 in the Assembly Health Committee, studies show children who are treated with cross-sex hormones for their gender confusion have “significant mental health issues,” that remain even after hormone therapy. Van Meter warned legislators that the state would be sued in the coming years for funding transgender affirming treatments for troubled and vulnerable children because they destroy healthy body tissue, sterilize the recipient, and cause irreversible damage.
The Food and Drug Administration (FDA) has documented thousands of deaths linked to the puberty-blocking drugs now increasingly given to children who suffer from gender dysphoria or claim to be “transgender.”
Between 2013 and June 2019, FDA recorded 41,213 adverse events, including 6,379 deaths and 25,645 “serious” reactions in patients who took the hormone blocker known as Lupron — the same drug given to children who say their gender identity is not consistent with their biological sex.
Leuprolide Acetate, known as Lupron, is clinically approved for treatment of prostate cancer in men, endometriosis in women, and, for a short period of time, “precocious puberty” — a condition in which children begin puberty at a significantly younger age than is considered normal.
Lupron is also being used — without formal FDA approval — as a puberty blocker on the increasing number of children and adolescents who are being diagnosed in the U.S. and the U.K. with gender dysphoria. This is being done — with the support of the American Academy of Pediatrics and the Endocrine Society — despite the fact there is no evidence that such hormonal treatments actually benefit children and adolescents with gender dysphoria.
Puberty blockers: Puberty blockers, also called puberty inhibitors, are drugs used to postpone puberty in children. These drugs are called gonadotropin-releasing hormone (GnRH) agonists, and they inhibit the action of testosterone. Delaying or temporarily suspending puberty is a medical treatment for children whose puberty started abnormally early (precocious puberty). They are also commonly used for children with idiopathic short stature and for whom these drugs can be used to promote development of long bones and increase adult height. Additionally, they are used for transgender children, to stop the development of features that they considered their wrong sex, with the intent to provide transgender youth more time to explore their identity.
In adults, the same drugs are used to treat endometriosis, prostate cancer, and other conditions
Form learning more about the dangers of these drug, please click on links below.
Gonadotropin-releasing hormone (GnRH) agonist: https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_agonist